Diversified Trust Co Raises Stake in Omnicell, Inc. (NASDAQ:OMCL)

Diversified Trust Co boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,870 shares of the company’s stock after buying an additional 2,326 shares during the quarter. Diversified Trust Co’s holdings in Omnicell were worth $435,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Neo Ivy Capital Management purchased a new position in shares of Omnicell in the 3rd quarter valued at about $78,000. Hsbc Holdings PLC acquired a new position in shares of Omnicell during the 3rd quarter worth approximately $200,000. Revisor Wealth Management LLC purchased a new position in Omnicell during the third quarter valued at $215,000. Strs Ohio boosted its holdings in Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after buying an additional 1,100 shares during the last quarter. Finally, Teza Capital Management LLC acquired a new stake in shares of Omnicell in the third quarter worth approximately $257,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Up 2.3 %

Shares of OMCL opened at $26.76 on Friday. The stock has a fifty day simple moving average of $29.34 and a two-hundred day simple moving average of $30.24. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $1.23 billion, a PE ratio of -58.17, a price-to-earnings-growth ratio of 92.77 and a beta of 0.80. Omnicell, Inc. has a 52-week low of $25.45 and a 52-week high of $75.07.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.17. The company had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. As a group, equities analysts forecast that Omnicell, Inc. will post 0.2 EPS for the current year.

Analyst Ratings Changes

Separately, Benchmark restated a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a report on Tuesday, April 30th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus target price of $42.20.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.